B M Lodde

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome
    B M Lodde
    GTTB NIDCR, National Institutes of Health, 10 Center Drive, Room 1N114, MSC 1190, Bethesda, MD 20892 1190, USA
    Ann Rheum Dis 65:195-200. 2006
  2. ncbi request reprint NOD mouse model for Sjögren's syndrome: lack of longitudinal stability
    B M Lodde
    Gene Therapy and Therapeutics Branch NIDCR, NIH, DHHS, Bethesda, MD 20892 1190, USA
    Oral Dis 12:566-72. 2006
  3. ncbi request reprint Rapamycin control of transgene expression from a single AAV vector in mouse salivary glands
    J Wang
    Gene Therapy and Therapeutics Branch, NIDCR, NIH, DHHS, Bethesda, MD 20892, USA
    Gene Ther 13:187-90. 2006
  4. ncbi request reprint Serum lipid levels in Sjögren's syndrome
    B M Lodde
    Gene Therapy and Therapeutics Branch National Institute of Dental and Craniofacial Research, National Institutes of Health, 10 Center Drive, Room 1N114, MSC 1190, Bethesda, MD 20892 1190, USA
    Rheumatology (Oxford) 45:481-4. 2006
  5. pmc Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjögren's syndrome
    N Roescher
    Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
    Oral Dis 18:96-106. 2012
  6. ncbi request reprint A recombinant adenoviral vector encoding functional vasoactive intestinal peptide
    B M Lodde
    Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, DHHS, Bethesda, MD 20892 1190, USA
    Biochem Biophys Res Commun 319:189-92. 2004
  7. pmc Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment
    B M Lodde
    Gene Therapy and Therapeutics Branch NIDCR, National Institutes of Health, 10 Center Drive, Building 10, Room 1N114, Bethesda, MD 20892 1190, USA
    Ann Rheum Dis 65:1406-13. 2006
  8. ncbi request reprint Adult heart block is associated with disease activity in primary Sjögren's syndrome
    B M Lodde
    Gene Therapy and Therapeutics Branch National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892 1190, USA
    Scand J Rheumatol 34:383-6. 2005

Detail Information

Publications8

  1. pmc Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome
    B M Lodde
    GTTB NIDCR, National Institutes of Health, 10 Center Drive, Room 1N114, MSC 1190, Bethesda, MD 20892 1190, USA
    Ann Rheum Dis 65:195-200. 2006
    ..The aetiology and pathogenesis are largely unknown; currently, only palliative treatment is available...
  2. ncbi request reprint NOD mouse model for Sjögren's syndrome: lack of longitudinal stability
    B M Lodde
    Gene Therapy and Therapeutics Branch NIDCR, NIH, DHHS, Bethesda, MD 20892 1190, USA
    Oral Dis 12:566-72. 2006
    ..Data collected over a 2-year period indicated a changing SS phenotype in these mice and this phenomenon was investigated...
  3. ncbi request reprint Rapamycin control of transgene expression from a single AAV vector in mouse salivary glands
    J Wang
    Gene Therapy and Therapeutics Branch, NIDCR, NIH, DHHS, Bethesda, MD 20892, USA
    Gene Ther 13:187-90. 2006
    ..Our results suggest that the rapamycin transcriptional regulation system delivered in a single AAV2 vector to SGs may be valuable for systemic protein replacement applications...
  4. ncbi request reprint Serum lipid levels in Sjögren's syndrome
    B M Lodde
    Gene Therapy and Therapeutics Branch National Institute of Dental and Craniofacial Research, National Institutes of Health, 10 Center Drive, Room 1N114, MSC 1190, Bethesda, MD 20892 1190, USA
    Rheumatology (Oxford) 45:481-4. 2006
    ..Serum lipid profiles in patients with Sjögren's syndrome (SS) have not been investigated. We hypothesized decreased lipid levels in SS patients and an inverse relationship with disease activity...
  5. pmc Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjögren's syndrome
    N Roescher
    Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
    Oral Dis 18:96-106. 2012
    ..Non-obese diabetic (NOD) mice develop an autoimmune exocrinopathy that shows similarities with Sjögren's syndrome. They provide an experimental model to study the pathoetiogenesis of this disease...
  6. ncbi request reprint A recombinant adenoviral vector encoding functional vasoactive intestinal peptide
    B M Lodde
    Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, DHHS, Bethesda, MD 20892 1190, USA
    Biochem Biophys Res Commun 319:189-92. 2004
    ..This is the first report showing the construction of a recombinant viral vector encoding biologically active VIP...
  7. pmc Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment
    B M Lodde
    Gene Therapy and Therapeutics Branch NIDCR, National Institutes of Health, 10 Center Drive, Building 10, Room 1N114, Bethesda, MD 20892 1190, USA
    Ann Rheum Dis 65:1406-13. 2006
    ..This article reviews the current literature on these approaches and assesses the lessons learnt about the pathogenesis of Sjögren's syndrome...
  8. ncbi request reprint Adult heart block is associated with disease activity in primary Sjögren's syndrome
    B M Lodde
    Gene Therapy and Therapeutics Branch National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892 1190, USA
    Scand J Rheumatol 34:383-6. 2005
    ..Therefore, we investigated the relationship between serum antibodies and heart block in adult SS patients...